AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03081780 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FATE-NK100
Description: Preparative regimen:~* Fludarabine 25 mg/m2 x 5 days start Day -6~* Cyclophosphamide 60 mg/kg x 2 days on Day -5 and -4~Apheresis cell collection (collected from the Donor Day - 8) will be enriched for FATE-NK100 per CMC. IL-2 at 6 million IU subcutaneously (SC) every other day (EOD) for 6 doses with Dose 1 on Day 0 (no sooner than 4 hours post NK cells) and last dose no later than Day +12.
Study NCT03561649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: This trial will be conducted by rheumatologists who can follow patients with SpA and conduct this trial in good conditions and in accordance with regulatory and legal recommendations.
Study NCT03681249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ShenqiDihuang Decoction
Description: ShenqiDihuang Decoction 150ml twice a day for 24 weeks 150ml twice a day for 24 weeks
Study NCT03681249 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ShenqiDihuang Decoction placebo
Description: traditional Chinese medicine placebo mimic ShenqiDihuang Decoction 150ml twice a day for 24 weeks
Study NCT04213495 — intervention group
Intervention type: OTHER
Intervention: Anesthesia
Description: Patients undergoing anesthesia from the cooperating Anesthesia center
Study NCT04505527 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lateral stepping
Description: Subjects will step laterally, changing direction every 10 m, thus alternating lead and lag limbs.
Study NCT04505527 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lateral stepping
Description: Subjects will step laterally, changing direction every 10 m, thus alternating lead and lag limbs.
Study NCT04505527 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Forward walking
Description: Subjects will have a typical forward walking
Study NCT03048227 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Measurement (CGM)
Description: Patients will manage their diabetes with the help of Continuous Glucose Measurements (Abbott Freestyle Navigator II).
Study NCT05172115 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional catheter-directed thrombolysis (CDT) with recombinant tissue plasminogen activator (rtPA)
Description: Conventional catheter-directed thrombolysis with fixed-dose of 24 mg tissue plasminogen activator infusion over 24 hours
Study NCT05172115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Subcutaneous enoxaparin twice-daily (1mg/kg)
Study NCT03929068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carbidopa-levodopa
Description: Motivated by the success of dopaminergic drugs in treating rigidity associated with Parkinson's disease, some neurologists have used carbidopa-levodopa to attempt to improve spasticity in ALS and PLS patients.
Study NCT03929068 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo will be given to maintain blinding of participants and study team.
Study NCT02723344 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: of Lactobacillus reuteri (L. reuteri; DSM 17938)
Description: Commercially available L. reuteri (deposited in the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) and referenced as DSM 17938; Gerber Soothe Colic Drops, 100 million CFU/5 drops; formerly known as L. reuteri ATCC 55730) will be used in the proposed study. L. reuteri (phylum Firmicutes) is a gram-positive anaerobic commensal bacteria found in the gut microbiome of humans. Independent testing of the viability of the commercial product will be conducted in our laboratories by diluting drops, plating on agar in triplicate, and anaerobic culturing at 37 oC. The commercial strain (DSM 17938) has been used to improve intestinal functions in infants and reduce symptoms of infantile colic.
Study NCT02723344 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sunflower and medium chain triglyceride oils
Description: Placebo
Study NCT00960219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-amino acid oxidase inhibition (DAAOI-1)
Description: 1g/day(500mg BID), oral, for 6 weeks
Study NCT00960219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1# BID, oral, for 6 weeks
Study NCT04708223 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct restorative treatment with fast-curing composites (Tetric PowerFill/ Tetric PowerFlow)
Description: Tooth (teeth) affected by dental caries or with an existing defective filling will be restored. Adhese Universal in self-etch mode, was used to prepare the surfaces for the composite fillings. Tetric PowerFill/ Tetric PowerFlow (test group) was cured for 3 s.
Study NCT04708223 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Direct restorative treatment with conventionally applied composites (Tetric EvoCeram Bulk Fill/ Tetric EvoFlow Bulk Fill)
Description: Tooth (teeth) affected by dental caries or with an existing defective filling will be restored. Adhese Universal in self-etch mode, was used to prepare the surfaces for the composite fillings. Tetric EvoCeram Bulk Fill/ Tetric EvoFlow Bulk Fill (control group) were conventionally cured for 10 s per increment.
Study NCT03333941 — intervention group
Intervention type: DEVICE
Intervention: ReCell® Autologous Cell Harvesting Device
Description: RES (Regenerative Epithelial Suspension) derived from the use of the ReCell® device will be applied over skin grafts meshed more widely than conventional autografting.
Study NCT00332670 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 10.000lux blue 1 hour every day during three weeks
Description: 10.000lux during 60 minutes, starting 1 hour after wake-up, during 3 weeks
Study NCT00332670 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: 50lux dim red 1 hour every day during three weeks
Description: 50 lux red light, 60 minutes every morning, starting 1 hour after wake-up, during three weeks
Study NCT01591083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden)
Description: Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients with Rockall score >=6 are randomized into the double oral dose group and the regular oral dose group. Patients with Rockall score \<6 are assigned to the control group.~In the double oral dose group, patients receive 40 mg oral esomeprazole twice daily for 11 days and followed by 40 mg once daily for 14 days. In the other two groups, patients receive 40 mg oral esomeprazole 40 mg once daily for 25 days.
Study NCT02207205 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Blood drawn from indwelling catheters versus direct venipuncture
Description: Evaluation of the source of blood samples on whole blood clotting time
Study NCT03034993 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging
Description: Subjects will receive text messages with reminders of their upcoming outpatient health care appointments at the Boston Health Care for the Homeless Program (BHCHP) clinic. The text message will indicate the time of the appointment and the location (e.g. Remember appointment Friday March 15 at 10am in the Yawkey building). Appointment reminder text messages will be sent 3 days ahead and again 1 day ahead of the appointment date. Medication related texts will be sent every other day and will be educational and motivational (e.g. Keep taking medications that way the doctor prescribed them, even if feeling fine). Mood related texts will also be sent every other day and ask about mood on a 1 to 5 scale. The participant will text back a response.
Study NCT01398111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate + Formoterol
Description: glycopyrrolate pMDI + formoterol pMDI
Study NCT01777178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low bicarbonate dialysis
Study NCT01948115 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: equimolar mixture of oxygen and nitrous oxide or medical air
Description: We need to include 150 patients for a period of 2 years. Patients will be randomized: 75 patients in each arm: 75 patients in group placebo (medical air), 75 patients in group treatment (equimolar mixture of oxygen and nitrous oxide).~Patients will be single-blind. The ECV be started at least 3 minutes after the start of administration. The maximum time of administration of the gas will be 15 minutes. Just after ECV, we compare success rate of intervention.
Study NCT01948115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: equimolar mixture of oxygen and nitrous oxide or medical air
Description: We need to include 150 patients for a period of 2 years. Patients will be randomized: 75 patients in each arm: 75 patients in group placebo (medical air), 75 patients in group treatment (equimolar mixture of oxygen and nitrous oxide).~Patients will be single-blind. The ECV be started at least 3 minutes after the start of administration. The maximum time of administration of the gas will be 15 minutes. Just after ECV, we compare success rate of intervention.
Study NCT02983747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRP Treatment(P)
Description: Ultrasound(Philips® iU22 ultrasound system) guided intra-disk injection using 2 ml of platelet rich plasma, containing 0.2 ml of calcium chloride(SINE®, SHANGHAI XINYI PHARMACEUTIAL Co . Ltd .) per treatment
Study NCT02983747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medication Treatment(Loxoprofen Sodium tablets,M)
Description: Loxoprofen Sodium tablets(LOXONNIN®, DAICHI SANKYO PHARMACEUTIAL (SHANGHAI) Co . Ltd .)，P.O., 60mg, three times a day
Study NCT02983747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medication Treatment(Loxoprofen Sodium tablets,M)
Description: Loxoprofen Sodium tablets(LOXONNIN®, DAICHI SANKYO PHARMACEUTIAL (SHANGHAI) Co . Ltd .)，P.O., 60mg, three times a day
Study NCT01818115 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrus Implant
Study NCT01398111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Description: glycopyrrolate pMDI
Study NCT01398111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: formoterol pMDI
Study NCT01398111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo pMDI
Study NCT01153412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment
Description: Osteopathic manipulation to determine balance and stability in elderly
Study NCT00922571 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FS Laser Surgery
Description: The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery. The intervention consists of the both surgery and the use of the device.
Study NCT00922571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FS Laser System
Description: The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery. The intervention consists of the both surgery and the use of the device.
Study NCT00571506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: Rosiglitazone 4 mg tablets by mouth daily for 3 months
Study NCT00571506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 30 mg tablet by mouth once daily
Study NCT04274647 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NON-STERILE, POWDER FREE NITRILE EXAMINATION GLOVES, LOW DERMATITIS POTENTIAL, TESTED FOR USE WITH CHEMOTHERAPY DRUGS - BLUE
Description: Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.
Study NCT02806050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: all patients will be treated with palbociclib, on a 3 weeks on, 1 week off cycle until progression
Study NCT02806050 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES PET
Description: all patients will have a FES PET at baseline
Study NCT02806050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: all patients will be treated with Letrozole daily until progression
Study NCT02265822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melatonin in children premedication
Study NCT02265822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam in children premedication
Study NCT01398176 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3 ounces of mushrooms
Description: 3 ounces of mushrooms consumed daily for 4 weeks
Study NCT01398176 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 6 ounces of mushrooms
Description: 6 ounces of mushrooms consumed daily for 4 weeks
Study NCT03834857 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Stentrode
Description: Implantation of Stentrode device
Study NCT04536142 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: A research MRI scan will be performed within 1 week prior to surgery and again 2 weeks after surgery. The surgical removal of the brain tumor(s) is not a component of this research. The MRI scan will perform both programs (diffusion MRI, resting state MRI) during the same single session. The healthy controls will obtain identical research scans with the second session between two and three weeks following the first session, since they will not undergo a surgery.
Study NCT04536142 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: neuropsychological tests and qualitative assessment
Description: Neuropsych Tests: COWA, Trails, RCFT, RAVLT, WMS-III subtests, NAB Digits, Grooved Pegboard, Stroop Color Word Test, verbal and spatial working memory, WRAT-IV, Word Reading subtest.~Standardized quality of life measures: MDASI-BT, FACT-Br, FrSBe
Study NCT01977573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: Film-coated tablets containing 0.5 mg, 1 mg, 2 mg, 5mg or matching placebo
Study NCT01977573 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: rhEPO
Description: Locally sourced rhEPO. All subjects who are randomized to the Control arm will receive rhEPO (epoetins or their biosimilars, or darbepoetin) as necessary per standard of care, to maintain Hgb levels within the target range. The decision around whether a subject requires rhEPO, selection of the type of rhEPO and rhEPO dose should be based on Investigator clinical judgment, with the historical rhEPO dose (where applicable) and the current Hgb value being considered..
Study NCT02030067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-3117
Study NCT03375866 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pretzels
Description: Subjects consume 240 kcal of pretzels daily for 16 weeks.
Study NCT03375866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed nuts
Description: Subjects consume 240 kcal of mixed nuts daily for 16 weeks.
Study NCT01045902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelox (Moxifloxacin, BAY12-8039)
Description: Moxifloxacin, 400 mg iv, od, switch after 6 doses (6 days) to 400 mg Moxifloxacin oral, od
Study NCT01045902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulbactam/Ampicillin
Description: Sulbactam/Ampicillin, 3 g iv, tid, switch after 18 doses (6 days) to 750 mg Sulbactam/Ampicillin oral, bid
Study NCT04477603 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impella ECP
Description: Subjects will receive the Impella ECP prior to high-risk percutaneous intervention. Device escalation or early termination of the study will be allowed for subjects as deemed necessary by the treating physician. Subjects will be followed until 30-days post-intervention.
Study NCT02658279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study NCT02101216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prurisol
Description: Experimental Drug
Study NCT02101216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziagen
Description: Active comparator
Study NCT02118467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Dose range 0.03 to 0.3 mcg/kg/minute, titrated to target blood pressure.
Study NCT02118467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Dose range 0.03 to 0.3 mcg/kg/minute, titrated to target blood pressure.
Study NCT02118467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Dose range 0.3 to 3.0 mcg/kg/minute, titrated to target blood pressure.
Study NCT02118467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin
Description: Dose range 0.1 to 0.6 milliunits/kg/minute, titrated to target blood pressure.
Study NCT02619942 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: D2 radical operation
Description: In D2 radical operation group(D2), the lymph node dissection is based on ligating the supplying vessels close to the right-side of superior mesenteric vein and clean up the surrounding lymph node and adipose tissue.
Study NCT02619942 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Complete mesocolic excision (CME)
Description: In complete mesocolic excision group (CME), the dissecting extent includes the lymphatic and fat tissues surrounding the root of ascending mesocolon, which situated on the surface of superior mesenteric vein, and the root of right half of transverse mesocolon, which situated on the surface of pancreas neck.
Study NCT01645215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib is a capsule in the form of 0.25mg , 1mg and 5mg, oral, once a day.
Study NCT01955642 — intervention group
Intervention type: DRUG
Intervention: Clopidogrel
Description: 75 mg milligrams per days of PLAVIX
Study NCT02786368 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control group
Description: A comparison group; no intervention for year 1, EHFP after 1 year of program implementation.
Study NCT02786368 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EHFP group
Description: Intervention group: training; inputs cost-sharing for EHFP activities.
Study NCT01467531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: 50mg q 24h
Study NCT01467531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rlipivirine
Description: 25mg q24h
Study NCT01467531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744
Description: 30mg q24h
Study NCT02195531 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education and feedback
Description: The education leaflets are information concerning Obstructive Sleep Apna (OSA) and CPAP treatment. The feedback reports are CPAP usage patterns.
Study NCT01818115 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IOL placement
Study NCT01790087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANX-188 Therapeutic Dose
Study NCT01790087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANX-188 Supratherapeutic dose
Study NCT01790087 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT01790087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Study NCT00602043 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: F-18 16 alpha-fluoroestradiol
Description: Undergo \[\^18F\] FES PET
Study NCT00602043 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Undergo standard clinical FDG PET/CT
Study NCT01441596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afatinib
Description: Afatinib monotherapy:once daily, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.
Study NCT00602043 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo \[\^18F\] FES PET
Study NCT00602043 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo standard clinical FDG PET/CT
Study NCT00602043 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo standard clinical FDG PET/CT
Study NCT00602043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04672694 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vagus nerve block
Description: Ropivacine 0.75% 2mL will be injected two times around the vagus nerve (just below the bifurcation of recurrent laryngeal nerve); one before starting the surgical resection of lung including complete mediasitnal lymph node dissection and one at the end of operation.
Study NCT04672694 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: No vagus nerve block
Description: No vagus nerve block will be conducted during the surgery.